Acarbose in the treatment of type I diabetes

Diabetes Care

Volumn 20, Issue 3, 1997, Pages 248-253

  Hollander, Priscilla ^a,d   Pi Sunyer, Xavier ^b   Coniff, Robert F ^c  

^a INTERNATIONAL DIABETES CENTER   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c BAYER CORPORATION   (United States)

^d DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; HEMOGLOBIN A1C; INSULIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; FLATULENCE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY;

EID: 0031027627     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.3.248     Document Type: Article

References (24)

1. Mauer SM, Steffes MW, Sutherland DER, Najarian JS, Michael AF, Brown BM: Studies of the rate of regression of the glomerular lesions in diabetic rats treated with pancreatic islet transplantation. Diabetes 24:280-285, 1975
2. Engerman RL, Bloodworth JMB, Nelson S: Relationship of microvascular disease in diabetes to metabolic control. Diabetes 26:760-769, 1977
3. Pirart J: Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1:168-188, 1978
4. Engerman RL, Kern TS: Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36:808-812, 1987
5. The DCCT Research Group: The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
6. Feldt-Rasmussen B, Mathiesen ER, Deckert T: Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin dependent diabetes. Lancet ii:1300-1304, 1986
7. Strowig S, Raskin P: Glycemic control and diabetic complications. Diabetes Care 15: 1126-1140, 1992
8. Aubell R, Boehme K, Berchtold P: Blood glucose concentrations and glycosuria during and after one year of acarbose therapy. Arzneimittelforschung 33:1314-1318, 1983
9. Damoiseaux P, Buysschaert M, Ketelslegers JM, Hillebrand IS, Lambert AE: Effect of acarbose on blood glucose profile of totally insulin-dependent diabetic patients. Acta Clin Belgica 38:5-11, 1983
10. Dimitriadis G, Karaiskos C, Raptis S: Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus. Horm Metab Res 18:253-255, 1986
11. Buber V: Effect of acarbose in non-insulin dependent diabetic patients during long-term treatment. In Proceedings of the First International Symposium on Acarbose, Montreux, October 1981. Creutzfeldt W, Ed. Amsterdam, Excerpta Medica, 1982, p. 266-274
12. Orimo H, Aklguguchi I, Shiraki M: Usefulness of acarbose in the management of non-insulin dependent diabetes in the aged. In Proceedings of the First International Symposium on Acarbose, Montreux, October 1981. Creutzfeldt W, Ed. Amsterdam, Excerpta Medica, 1982, p. 348-352
13. Sachse G, Maeser E, Lauber H, Federlin K: Diabetische Stoffwechsellage unter langerfristiger Acarbose Therapie. Therapiewoche 32:3587-3590, 1982
14. Helimi S, Corticelli P, Benhamou PY: Combination of insulin and sulfonylureas: a literature review. Am J Med 90:83S-86S, 1991
15. Rizza RA: Combined sulfonylurea and insulin therapy in insulin-dependent diabetes: research or clinical practice? Diabetes Care 8:511-514, 1985
16. McCulloch DK, Kurtz AB, Tatersall RB: A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition. Diabetes Care 6:483-487, 1983
17. Marena S, Tagliaferro V, Cavallero B, Pagani A, Montegrosso C, Bianchi W, Saccarinin P, Pagano G: Double-blind crossover study of acarbose in type I diabetic patients. Diabet Med 8:674-678, 1991
18. Hanefield M, Fischer S, Schulze J, Spangler M, Wargenau M, Schollberg K, Fücker K: Therapeutic potentials of acarbose as a first drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14:732-737, 1991
19. Coniff RF, Innerfield RJ: A multicenter, double-blind, placebo-controlled study of long-term efficacy and safety of acarbose (BAY g 5421) and SFU in the Rx of NIDDM inadequately controlled by maximal SFU. Diabetes 39 (Suppl. 1):109A, 1990
20. Pi-Sunyer FX: A multicenter, double-blind comparative study of long-term efficacy and safety of acarbose (Bay G 5421) vs placebo in the treatment of patients with insulin requiring type II diabetes mellitus. In New Aspects in Diabetes: Treatment Strategies with Alpha-glucosidase Inhibitors. Lefebvre PJ, Standl E, Eds. Berlin, New York, Walter de Gruyter, 1992, p. 235-236
21. Jenkins DJA, Taylor RH: Acarbose: dosage and interactions with sugars, starch and fibre. In Proceedings of the First International Symposium on Acarbose, Montreux, October 1981. Creutzfeldt W, Ed. Amsterdam, Excerpta Medica, 1982, p. 86-96
22. Johnson DG: New drugs for diabetes: acarbose. Drug Ther 12:219-226, 1982
23. Aubell R, Boehme K, Berchtold P: One-year acarbose treatment of diabetic outpatients: multicentre study part I: safety. In Proceedings of the First International Symposium on Acarbose, Montreux, October 1981. Creutzfeldt W, Ed. Amsterdam, Excerpta Medica, 1982, p. 360-362
24. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB: Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 18:817-824, 1995